Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

UC Davis researchers set out to identify biomarkers for early diagnosis of lung cancer

Despite decades of warnings about smoking, lung cancer is still the second-most common cancer and the leading cause of death from cancer in the U.S. Patients are often diagnosed only when their disease is already at an advanced stage and hard to treat. Researchers at the West Coast Metabolomics Center at UC Davis are trying to change that, by identifying biomarkers that could be the basis of early tests for lung cancer.

19 Aug 2015

Researchers refine breast cancer risk model to give more accurate assessment

A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than one million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher.

19 Aug 2015

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.

19 Aug 2015

MRI scanners can steer cell-based, tumour busting therapies to exact target sites in the body

Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.

19 Aug 2015

Survey identifies key factors linked to pediatric safety events in out-of-hospital emergent care situations

A national survey of more than 750 emergency medical services providers conducted by researchers at Oregon Health & Science University identified airway management skills, personal anxiety and limited pediatric care proficiency among key factors that may contribute to pediatric safety events for children in out-of-hospital emergent care situations.

19 Aug 2015

Astellas Farma Brasil named one of Top 20 places to work in Brazil

Astellas Farma Brasil is one of the Top 20 small- to medium-sized companies to work for in the country across all industries, according to the Great Place to Work Institute's latest rankings. The results are based on a survey of thousands of employees across multiple industries in Brazil.

18 Aug 2015

US-based clinical research spending drops 32%, show new data

Could the Sunshine Act be creating an unintentional downward trend in clinical research? An analysis of the U.S. government's Open Payments database shows that industry spending on U.S-based clinical research has dropped 32 percent in the first year-over-year comparison since Open Payments data started to be collected.

18 Aug 2015

Mylan sued in connection with ANDA filing for generic version of Zytiga

Mylan N.V. today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for Abiraterone Acetate Tablets, 250 mg.

18 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

Researchers describe central role of mTOR in ageing and age-related diseases

For some, TOR may bring to mind a Celtic mountain or perhaps an Internet privacy group. In the world of molecular biology it's a cellular pathway that's found in everything from yeast to mammals.

18 Aug 2015

Music therapy reduces anxiety in women undergoing surgical breast biopsies

A first-of-its-kind study published in the Journal of Clinical Oncology finds that music therapy lessened anxiety for women undergoing surgical breast biopsies for cancer diagnosis and treatment.

18 Aug 2015

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

A study from Massachusetts General Hospital Cancer Center researchers - the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients - reveals not only specific structural changes within patients' brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased.

18 Aug 2015

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.

18 Aug 2015

Chronic fatigue a long-term problem for testicular cancer survivors

A Norwegian population-based study reported in the Annals of Oncology has found a rise in the incidence of chronic fatigue a decade or more after treatment in testicular cancer survivors.

17 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

New ISCO-SCCA collaboration to elevate standard of monthly virtual personalized tumor board

The Idaho Society of Clinical Oncology held its annual Board of Directors retreat in Sun Valley, ID on July 24-26, 2015. The focus for the retreat was how to discuss strategies to improve the care of cancer patients in Idaho. During the meeting, ISCO board announced a partnership with the Seattle Cancer Care Alliance to collaborate with ISCO's monthly virtual personalized tumor board.

17 Aug 2015

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

17 Aug 2015

New system accurately and reliably captures patient experience with cancer drug side effects

In cancer clinical trials, symptom side effects patients experience, like nausea, are typically reported by doctors, and not directly by patients. Previous research has shown that doctors under-report these symptoms.

14 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

National Cancer Institute's PRO-CTCAE accurate and reliable compared to other patient-reported measures

A multicenter study involving Mayo Clinic researchers has found that the National Cancer Institute's Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), was accurate, reliable and responsive, compared to other, established patient-reported and clinical measures. The study is published today in the journal JAMA Oncology.

14 Aug 2015

Oncology News and Research

Further Reading

UC Davis researchers set out to identify biomarkers for early diagnosis of lung cancer

Researchers refine breast cancer risk model to give more accurate assessment

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

MRI scanners can steer cell-based, tumour busting therapies to exact target sites in the body

Survey identifies key factors linked to pediatric safety events in out-of-hospital emergent care situations

Astellas Farma Brasil named one of Top 20 places to work in Brazil

US-based clinical research spending drops 32%, show new data

Mylan sued in connection with ANDA filing for generic version of Zytiga

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

Researchers describe central role of mTOR in ageing and age-related diseases

Music therapy reduces anxiety in women undergoing surgical breast biopsies

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Chronic fatigue a long-term problem for testicular cancer survivors

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

New ISCO-SCCA collaboration to elevate standard of monthly virtual personalized tumor board

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

New system accurately and reliably captures patient experience with cancer drug side effects

CASI reports financial results for second quarter 2015

National Cancer Institute's PRO-CTCAE accurate and reliable compared to other patient-reported measures

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News